Invitae
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The last earnings update was 77 days ago. More info.
Add to Portfolio Compare Print
- Invitae has significant price volatility in the past 3 months.
NVTA Share Price and Events
7 Day Returns
1 Year Returns
NVTA Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Invitae (NVTA) | 8.7% | 13.6% | 4.2% | 184.3% | 199.3% | - |
| US Biotechs | -1% | -3.6% | -0.7% | -11.9% | 5.4% | 7.4% |
| US Market | -1.2% | 0.8% | 0.9% | 3.3% | 35.9% | 41.7% |
1 Year Return vs Industry and Market
- NVTA outperformed the Biotechs industry which returned -11.9% over the past year.
- NVTA outperformed the Market in United States of America which returned 3.3% over the past year.
NVTA Value
Is Invitae undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Invitae. This is due to cash flow or dividend data being unavailable. The share price is $24.48.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Invitae's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Invitae's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $-1.79 |
| NYSE:NVTA Share Price ** | NYSE (2019-07-22) in USD | $24.48 |
| United States of America Biotechs Industry PE Ratio | Median Figure of 35 Publicly-Listed Biotechs Companies | 19.44x |
| United States of America Market PE Ratio | Median Figure of 3,082 Publicly-Listed Companies | 17.86x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Invitae.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NYSE:NVTA Share Price ÷ EPS (both in USD) = 24.48 ÷ -1.79 |
-13.65x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Invitae is loss making, we can't compare its value to the US Biotechs industry average.
- Invitae is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
Invitae's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -13.65x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts |
39.2%per year |
| United States of America Biotechs Industry PEG Ratio | Median Figure of 26 Publicly-Listed Biotechs Companies | 0.79x |
| United States of America Market PEG Ratio | Median Figure of 2,119 Publicly-Listed Companies | 1.57x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Invitae, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Invitae's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $3.53 |
| NYSE:NVTA Share Price * | NYSE (2019-07-22) in USD | $24.48 |
| United States of America Biotechs Industry PB Ratio | Median Figure of 437 Publicly-Listed Biotechs Companies | 2.93x |
| United States of America Market PB Ratio | Median Figure of 5,248 Publicly-Listed Companies | 1.79x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NYSE:NVTA Share Price ÷ Book Value per Share (both in USD) = 24.48 ÷ 3.53 |
6.93x |
* Primary Listing of Invitae.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Invitae is overvalued based on assets compared to the US Biotechs industry average.
Value checks
We assess Invitae's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Invitae has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
NVTA Future Performance
How is Invitae expected to perform in the next 1 to 3 years based on estimates from 8 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Invitae's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- Invitae's earnings growth is expected to exceed the United States of America market average.
- Invitae's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NYSE:NVTA Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts | 39.2% |
| NYSE:NVTA Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts | 31.6% |
| United States of America Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 23% |
| United States of America Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 18.5% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 14% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.4% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 8 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 811 | 19 | 2 | |
| 2022-12-31 | 632 | -51 | 2 | |
| 2021-12-31 | 463 | -15 | -99 | 5 |
| 2020-12-31 | 336 | -115 | -144 | 8 |
| 2019-12-31 | 221 | -127 | -169 | 8 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 161 | -88 | -131 |
| 2018-12-31 | 148 | -92 | -129 |
| 2018-09-30 | 128 | -108 | -140 |
| 2018-06-30 | 109 | -115 | -136 |
| 2018-03-31 | 86 | -109 | -133 |
| 2017-12-31 | 68 | -98 | -123 |
| 2017-09-30 | 52 | -84 | -108 |
| 2017-06-30 | 40 | -76 | -105 |
| 2017-03-31 | 31 | -74 | -102 |
| 2016-12-31 | 25 | -76 | -100 |
| 2016-09-30 | 19 | -80 | -100 |
| 2016-06-30 | 15 | -85 | -97 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 8 Analyst Estimates (S&P Global) | See Below |
All data from Invitae Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 0.18 | 0.36 | 0.00 | 2.00 |
| 2022-12-31 | -0.52 | -0.51 | -0.52 | 2.00 |
| 2021-12-31 | -0.98 | -0.72 | -1.26 | 5.00 |
| 2020-12-31 | -1.45 | -0.80 | -1.86 | 7.00 |
| 2019-12-31 | -1.90 | -1.63 | -2.26 | 7.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | -1.79 |
| 2018-12-31 | -1.94 |
| 2018-09-30 | -2.29 |
| 2018-06-30 | -2.44 |
| 2018-03-31 | -2.68 |
| 2017-12-31 | -2.65 |
| 2017-09-30 | -2.53 |
| 2017-06-30 | -2.73 |
| 2017-03-31 | -2.84 |
| 2016-12-31 | -3.02 |
| 2016-09-30 | -3.11 |
| 2016-06-30 | -3.04 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Invitae will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Future performance checks
We assess Invitae's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Invitae has a total score of 5/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
NVTA Past Performance
How has Invitae performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Invitae does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Invitae's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Invitae's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Invitae Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 160.58 | -130.91 | 129.32 | 66.12 |
| 2018-12-31 | 147.70 | -129.36 | 122.51 | 63.50 |
| 2018-09-30 | 127.74 | -140.01 | 120.76 | 60.53 |
| 2018-06-30 | 108.52 | -135.69 | 114.25 | 56.26 |
| 2018-03-31 | 85.55 | -132.57 | 103.83 | 51.81 |
| 2017-12-31 | 68.22 | -123.38 | 91.29 | 46.47 |
| 2017-09-30 | 52.06 | -107.74 | 77.39 | 44.64 |
| 2017-06-30 | 40.19 | -105.30 | 65.10 | 44.62 |
| 2017-03-31 | 31.43 | -101.59 | 57.29 | 43.99 |
| 2016-12-31 | 25.05 | -100.26 | 51.72 | 44.63 |
| 2016-09-30 | 18.97 | -99.77 | 48.15 | 44.24 |
| 2016-06-30 | 14.88 | -97.32 | 45.25 | 43.89 |
| 2016-03-31 | 11.10 | -96.74 | 42.94 | 45.01 |
| 2015-12-31 | 8.38 | -89.78 | 38.53 | 42.81 |
| 2015-09-30 | 6.09 | -80.73 | 35.29 | 37.89 |
| 2015-06-30 | 4.22 | -70.82 | 31.34 | 32.31 |
| 2015-03-31 | 2.72 | -57.10 | 25.89 | 25.55 |
| 2014-12-31 | 1.60 | -47.49 | 21.27 | 22.06 |
| 2014-09-30 | 0.82 | -40.32 | 16.49 | 21.02 |
| 2014-06-30 | 0.56 | -34.75 | 13.31 | 19.92 |
| 2014-03-31 | 0.26 | -29.12 | 10.14 | 17.92 |
| 2013-12-31 | 0.15 | -24.99 | 8.20 | 16.04 |
| 2012-12-31 | -9.01 | 3.00 | 5.56 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Invitae has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Invitae has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Invitae improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Invitae's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Invitae has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
NVTA Health
How is Invitae's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Invitae's finances.
The net worth of a company is the difference between its assets and liabilities.
- Invitae is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Invitae's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 4.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Invitae Company Filings, last reported 3 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 316.41 | 74.83 | 281.22 |
| 2018-12-31 | 161.84 | 74.48 | 125.89 |
| 2018-09-30 | 179.40 | 58.49 | 129.18 |
| 2018-06-30 | 138.65 | 58.64 | 85.14 |
| 2018-03-31 | 101.96 | 58.55 | 54.97 |
| 2017-12-31 | 121.79 | 39.08 | 64.66 |
| 2017-09-30 | 125.39 | 39.03 | 76.91 |
| 2017-06-30 | 67.16 | 38.98 | 75.37 |
| 2017-03-31 | 82.30 | 38.92 | 96.78 |
| 2016-12-31 | 99.07 | 12.10 | 92.62 |
| 2016-09-30 | 70.84 | 12.95 | 66.75 |
| 2016-06-30 | 92.69 | 11.13 | 85.29 |
| 2016-03-31 | 114.51 | 9.15 | 103.87 |
| 2015-12-31 | 138.38 | 7.04 | 127.02 |
| 2015-09-30 | 161.10 | 4.79 | 147.25 |
| 2015-06-30 | 182.65 | 0.00 | 170.93 |
| 2015-03-31 | 206.36 | 0.00 | 184.33 |
| 2014-12-31 | 118.73 | 0.00 | 107.03 |
| 2014-09-30 | 65.14 | 0.00 | 59.14 |
| 2014-06-30 | 30.19 | 0.00 | 22.04 |
| 2014-03-31 | 49.29 | 2.00 | 43.07 |
| 2013-12-31 | 49.29 | 0.00 | 43.07 |
| 2012-12-31 | 24.00 | 0.00 | 21.80 |
- Invitae's level of debt (24.5%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (4.1% vs 24.5% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Invitae has sufficient cash runway for more than 3 years based on current free cash flow.
- Invitae has sufficient cash runway for 2.8 years if free cash flow continues to grow at historical rates of 7.3% each year.
Financial health checks
We assess Invitae's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Invitae has a total score of 5/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
NVTA Dividends
What is Invitae's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Invitae
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Invitae's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Invitae's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 8 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 18 Stocks | 2.3% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2017 Stocks | 2.4% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.8% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Invitae has not reported any payouts.
- Unable to verify if Invitae's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Invitae's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Invitae afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Invitae has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
NVTA Management
CEO
| COMPENSATION | $2,233,360 |
| AGE | 45 |
| TENURE AS CEO | 2.5 years |
CEO Bio
Dr. Sean E. George, Ph.D. is the Co-Founder of InVitae Corporation and has been its President since August 2012. Dr. George has been Chief Executive Officer of InVitae Corporation since January 9, 2017 and served as its Chief Operating Officer since August 2008 until January 9, 2017. He has held a number of executive management positions in the life science industry. He served as Chief Operating Officer of Navigenics, Inc. since 2007 until November 2009. He was Co-Founder and Chief Executive Officer of Locus Development Inc. Dr. George served as the President at Locus Development Inc. Dr. George served at Affymetrix, Inc., as Senior Vice President of Marketing, responsible for its marketing, corporate communications, product management, and CRM divisions. He served as Senior Vice President, Life Science Business at Affymetrix. Dr. George served as vice president of life science research at Affymetrix. Dr. George served at Invitrogen, Inc., as vice president of diagnostic solutions, managing its anatomical pathology diagnostic business and driving business to diagnostic and other tools companies. He served as Vice President, Labeling and Detection Business at Invitrogen. Dr. George was strategic planning director of Molecular Probes. Dr. George served as an associate at McKinsey & Company, where he served with various clients in the pharmaceutical and biotech and corporate finance practices. He has been a Director of InVitae Corporation since January 2010. He serves as Member of Scientific advisory board at Genia Technologies, Inc. (alternate name, Genia Corporation). He served as Director at Locus Development Inc. Dr. George received his B.S. in microbiology and molecular genetics from the University of California, Los Angeles, his M.S. in molecular biology from the University of California, Santa Barbara and his Ph.D. in molecular genetics from the University of California, Santa Cruz.
CEO Compensation
- Sean's compensation has been consistent with company performance over the past year, both up more than 20%.
- Sean's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Invitae management team in years:
- The tenure for the Invitae management team is about average.
Management Team
Sean George
Co-Founder
$2M
45
2.5 yrs
Lee Bendekgey
Secretary & COO
$1M
61
2.1 yrs
Katherine Stueland
Chief Commercial Officer
$1M
43
2.8 yrs
Randy Scott
Executive Chairman
$322K
61
2.5 yrs
Shelly Guyer
Chief Financial Officer
$1M
59
2.1 yrs
Laura D'Angelo
Head of Investor Relations
Tom Brida
General Counsel
48
2.5 yrs
Robert Nussbaum
Chief Medical Officer
$803K
69
3.9 yrs
Eric Olivares
Head of Clinical Operations & Assay Development
2.4 yrs
Alex Furman
Executive Officer of Organizational Development
1.2 yrs
Board of Directors Tenure
Average tenure and age of the Invitae board of directors in years:
- The tenure for the Invitae board of directors is about average.
Board of Directors
Sean George
Co-Founder
$2M
45
9.5 yrs
Randy Scott
Executive Chairman
$322K
61
6.9 yrs
Eric Aguiar
Independent Director
$96K
57
8.8 yrs
Geoff Crouse
Independent Director
$96K
48
7.3 yrs
Christine Gorjanc
Independent Director
$91K
62
3.7 yrs
Elizabeth McNally
Member of Advisory Board
Chitra Nayak
Independent Director
$165K
55
0.8 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 23. May 19 | Sell | Katherine Stueland | Individual | 20. May 19 | 20. May 19 | -6,474 | $18.21 | $-117,892 | ||
| 23. May 19 | Sell | Lee Bendekgey | Individual | 20. May 19 | 20. May 19 | -6,851 | $18.21 | $-124,757 | ||
| 23. May 19 | Sell | Sean George | Individual | 20. May 19 | 20. May 19 | -24,282 | $18.21 | $-442,175 | ||
| 23. May 19 | Sell | Thomas Brida | Individual | 20. May 19 | 20. May 19 | -2,146 | $18.21 | $-39,079 | ||
| 22. May 19 | Sell | Shelly Guyer | Individual | 20. May 19 | 20. May 19 | -5,513 | $18.21 | $-100,392 | ||
| 22. May 19 | Sell | Robert Nussbaum | Individual | 20. May 19 | 20. May 19 | -7,202 | $18.21 | $-131,148 | ||
| 18. Apr 19 | Sell | Katherine Stueland | Individual | 16. Apr 19 | 16. Apr 19 | -1,000 | $25.23 | $-25,230 | ||
| 29. Nov 18 | Sell | Eric Aguiar | Individual | 27. Nov 18 | 27. Nov 18 | -10,000 | $13.50 | $-135,000 | ||
| 20. Sep 18 | Sell | Patricia Dumond | Individual | 18. Sep 18 | 20. Sep 18 | -645 | $16.67 | $-10,695 | ||
| 12. Sep 18 | Sell | Katherine Stueland | Individual | 09. Sep 18 | 09. Sep 18 | -595 | $13.62 | $-8,104 | ||
Management checks
We assess Invitae's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Invitae has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
NVTA News
Simply Wall St News
Could Invitae Corporation's (NYSE:NVTA) Investor Composition Influence The Stock Price?
Taking a look at our data on the ownership groups (below), it's seems that institutional investors have bought into the company. … View our latest analysis for Invitae NYSE:NVTA Ownership Summary, July 10th 2019 What Does The Institutional Ownership Tell Us About Invitae? … Insider Ownership Of Invitae While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders.
Simply Wall St - – Full articleHave Insiders Been Selling Invitae Corporation (NYSE:NVTA) Shares?
So we'll take a look at whether insiders have been buying or selling shares in Invitae Corporation (NYSE:NVTA). … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.' View our latest analysis for Invitae Invitae Insider Transactions Over The Last Year Over the last year, we can see that the biggest insider sale was by the Co-Founder, Sean George, for US$442k worth of shares, at about US$18.21 per share. … Insiders sold Invitae shares recently, but they didn't buy any.
Simply Wall St - – Full articleImagine Holding Invitae (NYSE:NVTA) Shares While The Price Zoomed 327% Higher
For example, the Invitae Corporation (NYSE:NVTA) share price rocketed moonwards 327% in just one year. … But the share price has really rocketed in response gaining 327% as previously mentioned. … But if the share price does moderate a bit, there might be an opportunity for high growth investors.
Simply Wall St - – Full articleDo Institutions Own Invitae Corporation (NYSE:NVTA) Shares?
Every investor in Invitae Corporation (NYSE:NVTA) should be aware of the most powerful shareholder groups. … With a market capitalization of US$2.0b, Invitae is a decent size, so it is probably on the radar of institutional investors. … Taking a look at our data on the ownership groups (below), it's seems that.
Simply Wall St - – Full articleInvitae Corporation (NYSE:NVTA): What's The Analyst Consensus Outlook?
Invitae Corporation's (NYSE:NVTA) most recent earnings announcement in December 2018 … company earnings became less negative compared to the previous year's level
Simply Wall St - – Full articleAre Insiders Selling Invitae Corporation (NYSE:NVTA) Stock?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … So before you buy or sell Invitae Corporation (NYSE:NVTA), you may well want to know whether insiders have been buying or selling. … But logic dictates you should pay some attention to whether insiders are buying or selling shares.
Simply Wall St - – Full articleInvitae Corporation (NYSE:NVTA): Is Healthcare An Attractive Sector Play?
operates in the healthcare industry, … The growth in development of new drugs for unmet needs, as well as the ongoing and increasing need for biotech drugs as Baby Boomer generation continues to age, are growth drivers for the positive outlook in the biotech industry over the long term … Healthcare analysts are forecasting for the entire industry,
Simply Wall St - – Full articleBefore You Buy Invitae Corporation's (NYSE:NVTA), Consider This
The other type of risk, which cannot be diversified away, is market risk. … Every stock in the market is exposed to this risk, which arises from macroeconomic factors such as economic growth and geo-political tussles just to name a few. … The most widely used metric to quantify a stock's market risk is beta, and the market as a whole represents a beta of one.
Simply Wall St - – Full articleMarch Top Growth Stocks To Buy
Its expected double-digit top-line and bottom-line growth exceeds its peers, and its financially stable position lessens the chances of risk. … Furthermore, the high growth of over 100% in operating cash flows indicates that a large portion of this earnings increase is high-quality, day-to-day cash generated by the business, rather than one-offs. … NasdaqGS:WIX Future Profit Mar 18th 18 For more financially robust companies with high growth potential to enhance your portfolio, explore this interactive list of fast growing companies.
Simply Wall St - – Full articleWhere Invitae Corporation (NYSE:NVTA) Stands In Terms Of Earnings Growth Against Its Industry
See our latest analysis for Invitae Was NVTA's recent earnings decline worse than the long-term trend and the industry? … I prefer to use data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … Each year, for the past five years Invitae's top-line has grown by 88.76% on average, signalling that the company is in a high-growth phase with expenses racing ahead revenues, leading to annual losses.
Simply Wall St - – Full articleNVTA Company Info
Description
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. The company also operates AltaVoice, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Details
| Name: | Invitae Corporation |
| NVTA | |
| Exchange: | NYSE |
| Founded: | 2010 |
| $2,293,900,921 | |
| 93,705,103 | |
| Website: | http://www.invitae.com |
| Address: |
Invitae Corporation 1400 16th Street, San Francisco, California, 94103, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NYSE | NVTA | Common Stock | New York Stock Exchange | US | USD | 12. Feb 2015 | |
| DB | IV8 | Common Stock | Deutsche Boerse AG | DE | EUR | 12. Feb 2015 | |
| LSE | 0JDB | Common Stock | London Stock Exchange | GB | USD | 12. Feb 2015 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/07/23 01:02 |
| End of day share price update: | 2019/07/22 00:00 |
| Last estimates confirmation: | 2019/07/12 |
| Last earnings filing: | 2019/05/07 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
